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Uncontrolled fibroblast growth factor (FGF) signaling can lead to human diseases, necessitating multiple
layers of self-regulatory control mechanisms to keep its activity in check. Herein, we demonstrate that FGF9
and FGF20 ligands undergo a reversible homodimerization, occluding their key receptor binding sites. To test
the role of dimerization in ligand autoinhibition, we introduced structure-based mutations into the dimer
interfaces of FGF9 and FGF20. The mutations weakened the ability of the ligands to dimerize, effectively
increasing the concentrations of monomeric ligands capable of binding and activating their cognate FGF
receptor in vitro and in living cells. Interestingly, the monomeric ligands exhibit reduced heparin binding,
resulting in their increased radii of heparan sulfate-dependent diffusion and biologic action, as evidenced by
the wider dilation area of ex vivo lung cultures in response to implanted mutant FGF9-loaded beads. Hence,
our data demonstrate that homodimerization autoregulates FGF9 and FGF20’s receptor binding and concen-
tration gradients in the extracellular matrix. Our study is the first to implicate ligand dimerization as an
autoregulatory mechanism for growth factor bioactivity and sets the stage for engineering modified FGF9
subfamily ligands, with desired activity for use in both basic and translational research.
Fibroblast growth factor (FGF) signaling plays pleiotropic
roles throughout the life spans of mammalian organisms, rang-
ing from germ cell maturation, mesoderm induction, body plan
formation, and organogenesis during embryonic development
to serum phosphate homeostasis and glucose, bile acid, lipid,
and cholesterol metabolism in the adult (3, 23, 27, 28, 57, 60,
62). The diversity of FGF signaling is underscored by virtue of
the fact that aberrant FGF signaling leads to a wide array of
human diseases, including skeletal and olfactory/reproductive
syndromes, phosphate wasting disorders, and cancer (16, 60,
67). Recent data also implicate dysregulated FGF signaling in
the etiology of neurodegenerative disorders, such as major
depressive disorder and Parkinson’s disease (10, 63, 64).
Based on pairwise sequence homology and phylogeny, the 18
bona fide mammalian FGFs (FGF1 to FGF10 and FGF16 to
FGF23) are divided into six subfamilies (45). Five FGF sub-
families have high-to-moderate affinity for pericellular heparan
sulfate (HS) glycosaminoglycans and thus diffuse locally within
tissues to act in a paracrine fashion, whereas the poor affinity
of the FGF19 subfamily for HS enables this subfamily to act in
an endocrine manner (28, 38). All FGFs share a core homology
region of about 120 amino acids, which fold into 12 antiparallel
 strands (1 to 12) that are arranged into three sets of
four-stranded  sheets (-trefoil fold) (39). The globular FGF
core domain is flanked by highly divergent N- and C-terminal
extensions, which are the principal regions responsible for the
different biology of FGFs.
FGFs exert their diverse actions by binding and activating
FGF receptors (FGFRs) in an HS-dependent fashion (51, 53,
69). There are four distinct mammalian FGFR genes (FGFR1
to FGFR4), each coding for a single-pass transmembrane ty-
rosine kinase receptor whose ectodomain consists of three
immunoglobulin-like domains (D1 to D3) connected by flexi-
ble linkers and whose intracellular domain contains the con-
served tyrosine kinase domain flanked by the juxtamembrane
(JM) and C-terminal regions (38). The 210-amino-acid-long
D2-D3 segment of the ectodomain is both necessary and suf-
ficient for ligand binding (20, 51, 52, 58, 70).
FGF signaling is tightly regulated by spatial and temporal
expression of ligands, receptors, HS cofactors, and most criti-
* Corresponding author. Mailing address: Department of Pharma-
cology, New York University School of Medicine, 550 First Avenue,
New York, NY 10016. Phone: (212) 263-2907. Fax: (212) 263-7133.
E-mail: moosa.mohammadi@nyumc.org.
 Present address: Department of Structural Biology, Sloan-Ketter-
ing Institute, New York, NY 10065.
† Present address: 454 Life Sciences Corporation, 1 Commercial St.,
Branford, CT 06405.
‡ Present address: Serono Inc., One Technology Place, Rockland,
MA 02370.
§ Supplemental material for this article may be found at http://mcb
.asm.org/.












cally by means of FGF-FGFR binding specificity. The tissue-
specific alternative splicing in the D3 domain of FGFR1 to
FGFR3 is the main mechanism by which FGF-FGFR binding
specificity is regulated. This splicing event gives rise to epithe-
lial “b” isoforms (FGFR1b to FGFR3b) and mesenchymal “c”
isoforms (FGFR1c to FGFR3c) (24, 25, 47, 68), which differ
from one another at the primary sequences of their key ligand
binding regions and thus in their FGF binding specificity/pro-
miscuity profiles. Most FGFs are also expressed in either epi-
thelial or mesenchymal tissues and exhibit specificity for FGFR
isoforms expressed in the opposite tissues. This results in the
establishment of a bidirectional signaling loop between the
epithelium and mesenchyme that is essential for organogenesis
and tissue homeostasis. It is well established that FGF7 and
FGF10, which are expressed exclusively in the mesenchyme,
activate specifically FGFR2b to mediate mesenchymal-to-epi-
thelial signaling in the lung, prostate, and lacrimal, mammary,
and salivary glands (19, 29, 35, 36, 59). Several lines of genetic
and biochemical evidence suggest that the members of the
FGF9 subfamily, which includes FGF9, FGF16, and FGF20,
convey the reciprocal signaling from the epithelium to the
mesenchyme. In the prostate, the epithelial-specific FGF9 has
been shown to activate mesenchymal FGFR3c isoforms (25).
In the heart, FGF9, FGF16, and FGF20 in the epicardium and
endocardium stimulate myocardial proliferation and differen-
tiation in vivo, acting redundantly through FGFR1c and
FGFR2c (32). Analysis of FGF9-deficient mice has identified
FGF9 as a reciprocal epithelial-to-mesenchymal signal re-
quired for morphogenesis of the lung, cecum, small intestine,
and inner ear (14, 49, 65, 71). In addition, studies in zebra fish
show that FGF16 and FGF20 are apical ectodermal ridge
factors that are required for pectoral fin bud outgrowth and, in
general, for cell proliferation and differentiation of the mes-
enchyme (41, 66).
In light of the key role of the FGF9 subfamily in tissue
homeostasis, it is essential to investigate the molecular mech-
anisms by which the activity of this subfamily is regulated. Our
previous structural and in vitro studies of FGF9 showed that
homodimerization masks FGF9’s key receptor binding sites,
suggesting that ligand dimerization may autoinhibit FGF9’s
biologic activity (50). In this report, we show that, like FGF9,
FGF20 also homodimerizes in the crystal and in solution.
Characterization of the dimer interface mutations in vitro and
in living cells demonstrates that ligand homodimerization au-
toinhibits FGF9 and FGF20 signaling by suppressing both re-
ceptor binding and HS-dependent diffusion in the extracellular
matrix (ECM). Our study is the first to implicate ligand dimer-
ization as an autoregulatory mechanism in growth factor bio-
activity.
MATERIALS AND METHODS
Protein expression and purification. FGF20 crystals were grown using bacte-
rially expressed full-length human FGF20 (Met-1 to Thr-211; velafermin, CG-
53135 [30]) provided by CuraGen (1). Validation of the structural data was
performed using N-terminally six-His-tagged full-length human FGF20 (Met-1
to Thr-211), untagged full-length human FGF9 (Met-1 to Ser-208), and N-
terminally six-His-tagged full-length human FGF16 (Met-1 to Arg-207) ex-
pressed in Escherichia coli in the lab (50). Single, double, and triple mutations
(Table 1) were introduced into both FGF9 and FGF20 using the QuikChange
site-directed mutagenesis kit (Stratagene, La Jolla, CA). Competent E. coli
BL21(DE3) cells were transformed with wild-type or mutated FGF9, FGF20, or
FGF16 expression plasmids. Transformants were grown at 37°C to an optical
density of 0.5 before inducing protein expression with 1 mM isopropyl-1-thio-
beta-D-galactopyronoside. Four hours after induction, the cells were harvested
and stored frozen until further use. Spun bacterial cell pellets were lysed using a
French press in 25 mM HEPES buffer (pH 7.5) containing 150 mM NaCl, 5 mM
EDTA, 10% glycerol, and 0.5 mM phenylmethylsulfonyl fluoride. The soluble
fraction containing the wild-type or mutated FGF9 proteins was subsequently
precipitated using saturated ammonium sulfate overnight at 4°C. Following cen-
trifugation, the protein pellets containing the FGF9 ligand were redissolved in 25
mM HEPES buffer (pH 7.5) and subjected to heparin affinity chromatography
using a HiTrap heparin affinity column (GE Healthcare, Piscataway, NJ), fol-
lowed by size exclusion chromatography on a HiLoad 16/60 Superdex 75 column
(GE Healthcare, Piscataway, NJ) equilibrated with 25 mM HEPES buffer (pH
7.5) and 1 M NaCl. Wild-type and mutated FGF20 proteins, as well as FGF16
and the ligand binding region of FGFR1c (Asp-141 to Arg-365), were refolded
from bacterial inclusion bodies, as previously described (22, 51). Correctly folded
FGF20, FGF16 ligands, and FGFR1c ectodomain were purified using sequential
heparin affinity and size exclusion chromatography. Protein concentrations were
determined spectrophotometrically under denaturing conditions using extinction
coefficients at 280 nm and verified by running 2 g of each protein on a sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis gel (see Fig. S3 in the
supplemental material).
Crystallization, data collection, structure determination, and refinement.
Crystals of FGF20 were grown by vapor diffusion at 20°C using the hanging drop
method. One microliter of FGF20 protein solution (10 mg/ml in 25 mM Na
TABLE 1. Description of the FGF9 and FGF20 mutants




None Wild type FGF20wt 54.5 65.6
E198A Single mutation FGF20E198A 55 63.7
L207A Single mutation FGF20L207A 56.5 58.1
L208A Single mutation FGF20L208A 55.5 61.7
L207A, L208A Double mutation FGF20L207A/L208A 59.5 48.2
FGF9
None Wild type FGF9wt 59.5 48.2
D195A Single mutation FGF9D195A 62 41.4
L200A Single mutation FGF9L200A 66 32.4
I204A Single mutation FGF9I204A 65 34.4
L205A Single mutation FGF9L205A 65.5 33.3
I204A, L205A Double mutation FGF9I204A/L205A 68 28.6
L200A, I204A, L205A Triple mutation FGF9L200A/I204A/L205A 68.5 27.7
D195A, I204A, L205A Triple mutation FGF9D195A/I204A/L205A 70 25.3
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phosphate buffer, pH 7.4, and 50 mM Arg-HCl) was mixed with 1 l of reservoir
buffer (0.1 M Tris-HCl [pH 8.5], 0.2 M Li2SO4, 15% glycerol, and 13% polyeth-
ylene glycol 2000). FGF20 crystals belong to the primitive rhombohedral R3
space group, with unit cell dimensions of a  b  102.14 Å and c  119.80 Å and
a solvent fraction of 50% (assuming molecular density of 1.30 g/ml). A single
FGF20 crystal was directly flash frozen in the cryostream of liquid nitrogen, and
the diffraction data were recorded on a charge-coupled-device detector at beam-
line X4A at the National Synchrotron Light Source, Brookhaven National Lab-
oratory, and processed using HKL2000 (48). A molecular replacement solution
for the two copies of FGF20 in the asymmetric unit was found using the program
AMoRe (40) and the FGF9 crystal structure (Protein Data Bank identification
[PDB ID] 1IHK) (50) as a search model. The program O (26) was used for model
building into the 2Fo-Fc and Fo-Fc maps, and CNS was used for rigid body,
positional, and B-factor refinements (4). Tight, noncrystallographic symmetry
restraints were imposed throughout the refinement for the backbone atoms of
the two FGF20 molecules in the asymmetric unit. Data collection, refinement,
and atomic model statistics are summarized in Table 2.
Size exclusion chromatography. Due to the poor solubility of the FGF9 sub-
family members in physiological salt buffers, column chromatography was carried
out in 25 mM HEPES buffer (pH 7.5) containing 1 M NaCl. To calibrate the
column (HiLoad 16/60 Superdex 75; GE Healthcare, Piscataway, NJ), 300 l of
a mixture of protein standards were injected, and the proteins were eluted using
an isocratic flow (1 ml/min). The following protein standards from Sigma-Aldrich
were used: aprotinin (6.5 kDa, 1.4 mg/ml), RNase A (13.7 kDa, 2.0 mg/ml),
carbonic anhydrase (30 kDa, 0.5 mg/ml), ovalbumin (44.3 kDa, 2.0 mg/ml),
and bovine serum albumin (66 kDa, 1.8 mg/ml). The equation y  1.1632x 
6.2746 was obtained from a linear fit, generated by plotting the logarithm of
molecular weights of the standards (y) against their respective elution volumes
per the elution volume of blue dextran (2 MDa, 0.6 mg/ml) (x). A total of 300
l of purified wild-type and mutated FGF9 (400 g/ml  17 M), FGF20 (460
g/ml  16.2 M, 230 g/ml  8.1 M, or 115 g/ml  4.1 M), or FGF16 (210
g/ml  7.3 M) proteins were injected, and the molecular sizes for FGF9, -20,
and -16 proteins were estimated by solving the above-described equation for “y”
and taking its inverse logarithm.
The molecular size estimation of 17 M wild-type FGF9 or 17 M
FGF9D195A/I204A/L205A alone or with various concentrations of heparin dode-
casaccharide (DS) (at 0, 2.1, 4.3, 8.5, 17.0, 34.0, 68.0, and 136 M) was performed
by injecting 350 l of each mixture onto a HiLoad 16/60 Superdex 200 (GE
Healthcare, Piscataway, NJ). The sizes were calculated by taking the inverse
logarithm of “y” using an equation, y  1.5565x  7.545, which was obtained
by calibrating the column, as described above.
SPR experiments and data processing. Surface plasmon resonance (SPR)
measurements were performed on the Biacore 2000 instrument (GE Healthcare,
Piscataway, NJ). For ligand-receptor interactions, purified wild-type or mutated
FGF9 or FGF20 was immobilized using either amine coupling on a carboxy-
methyl (CM5) biosensor chip (GE Healthcare, Piscataway, NJ) or oriented
coupling using the Ni-nitrilotriacetic acid biosensor chip (GE Healthcare, Pis-
cataway, NJ), according to manufacturer’s instructions, at a density of 1,800
resonance units and a flow rate of 5 l/min in acetate buffer (pH 5.5). Eight
different concentrations (from 50 nM to 2 M) of purified FGFR1c were pre-
pared in HBS-EP buffer (10 mM HEPES-NaOH [pH 7.4], 150 mM NaCl, 3 mM
EDTA, 0.005% [vol/vol] polysorbate 20; GE Healthcare, Piscataway, NJ) and
injected over the chip at a flow rate of 50 l/min. The association and dissocia-
tion phases were 250 and 180 s, respectively. The chip was regenerated in acetate
buffer (pH 4.5), supplemented with 2 M NaCl. The equilibrium dissociation
constants (KD) were calculated using BIAevaluation software 4.1 (GE Health-
care, Piscataway, NJ) by plotting the average maximal response at the end of the
association phase (Req) for each concentration against the concentration of
FGFR1c. The plots were then examined for goodness (2 test) of the model fit.
Good fits were obtained, as the 2 tests were calculated to be less than 10% of
Rmax for the reported plots. For each concentration, the signal was corrected
against the control surface (fibroblast homologous factor 1b immobilized to 1,800
response units [RUs]) to eliminate any refractive index changes due to nonspe-
cific binding. Similar KD values were obtained using a global fitting of the
association and dissociation phases to a Langmuir 1:1 binding model, as previ-
ously described (22).
For heparin affinity measurements, biotinylated heparin (Sigma, St. Louis,
MO) was noncovalently immobilized on a streptavidin-coated chip (GE Health-
care, Piscataway, NJ) at a density of approximately 140 RUs. Wild-type and
mutated FGF9 or FGF20 proteins were then passed over the chip at 80 nM for
FGF9 and 60 nM for FGF20. In addition, wild-type FGF9, FGF16, and FGF20
were injected over the chip at 40 nM each. Association and dissociation were
allowed to occur for 250 and 350 s, respectively. For each concentration, the
signal was corrected against the control surface (immobilized biotin) to eliminate
any refractive index changes due to nonspecific binding.
BaF3 receptor stimulation assay. The interleukin-3 (IL-3)-dependent murine
pro-B BaF3 cell line was transduced with lentiviral-based expression vectors for
FGFR1c, as previously described (13). Cells stably expressing FGFR1c were
selected using 1.2 mg/ml Geneticin in the presence of 5 ng/ml IL-3 for 14 days
and then maintained under selection in RPMI medium supplemented with 10%
fetal bovine serum, 50 nM beta-mercaptoethanol, 100 U/ml penicillin, 100 mg/ml
streptomycin sulfate, 1.2 mg/ml Geneticin, and 5 ng/ml murine IL-3 (R&D
Systems, Minneapolis, MN). Cells were washed in phosphate-buffered saline
(PBS) to remove IL-3 and plated at 1  104 cells per well in triplicate in a 96-well
plate in IL-3-free media containing 100 ng/ml wild-type or mutated FGF9 or
FGF20 ligands and 5 g/ml heparin. Bioluminescent measurement of ATP was
assessed as an indicator of cell number using the ViaLight Plus cell proliferation/
cytotoxicity kit (Lonza Rockland, Inc., Rockland, ME), according to the manu-
facturer’s instructions. Measurements were taken on the day cells were plated
(day 0) and every 24 h thereafter up to 72 h following ligand stimulation.
Experiments were repeated two independent times.
To study the effect of heparin on receptor activation, BaF3 cells (treated as
described above) were stimulated with IL-3-free media containing 100 ng/ml
wild-type FGF9 or FGF9D195A/I204A/L205A plus various concentrations of heparin
(0.3125, 0.625, 1.25, 2.5, 5, 10, 20, 40, and 80 g/ml). Bioluminescence measure-
ments were performed, as described above, with measurements taken in tripli-
cate every 24, 48, and 72 h following ligand stimulation. Experiments were
repeated two independent times.
pERK stimulation assay. BaF3/FGFR1c cells were starved of IL-3 and stimu-
lated with 100 ng/ml of wild-type or mutated FGF9 and FGF20 ligands in the
presence of 5g/ml heparin for 10 min, and lysates were collected. Lysates were then
analyzed using the Millipore 8-plex phosphoprotein detection kit. All experiments
were performed in duplicate, and each sample was evaluated in triplicate wells.
In-vitro proliferation assay of isolated lung mesenchyme. Embryonic day 12.5
(E12.5) mouse lung was isolated and treated with trypsin/pancreatin (Sigma, St.
Louis, MO) for 5 to 10 min at 4°C. The distal mesenchyme was separated from
the distal epithelium using fine tungsten needles, resuspended in the culture
medium DMEM (F-12 supplemented with 5% fetal bovine serum and Glu-
tamax), and plated on two-well chamber slides. Mesenchymal cells were cultured




















No. of protein atoms .....................................................2,510
No. of SO4 ions ..............................................................6












b Value in parentheses is for the highest-resolution shell: 2.59 to 2.5 A˚.
c Rcryst/Rfree  100  
hkl {Fo(hkl)  Fc(hkl)}/
hkl Fo(hkl), where Fo
(0	) and Fc are the observed and calculated structure factors, respectively. A
total of 5% of the reflections were used for calculation of Rfree.
d For bonded protein atoms.
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up to 70 to 80% confluence (24 to 36 h), then transferred to a defined (serum-
free) medium, and cultured for an additional 18 h. The cells were then supple-
mented with 20 ng/ml of wild-type and mutated FGF9 proteins and cultured for an
additional 12 h. Stimulation with 300 nM wild-type FGF9 or FGF9D195A/I204A/L205A
was also performed to test whether the differences in FGFR activation among
the proteins are still present at a concentration near the dissociation constant
(Kd) of ligand dimerization. At the end of this period, bromodeoxyuridine
(BrdU) was added to the culture medium, and the cells were incubated for an
additional hour. Cells were then washed with PBS and fixed in 2% paraform-
aldehyde for 20 min. Before BrdU detection, cells were postfixed with 20°C
acetone for 5 min. BrdU incorporation was detected using a BrdU detection kit,
as described by the manufacturer (GE Healthcare, Piscataway, NJ). In addition,
nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). Images of BrdU
and DAPI staining (10 frames from each slide) were taken using a Leica fluo-
rescent microscope, and BrdU- and DAPI-positive cells were counted using the
ImageJ program. The data were analyzed by Student’s t test, and the results were
determined to be significant if P was 0.01. BrdU labeling of lung mesenchymal
cultures was repeated three times.
FGF bead implantation in ex vivo lung cultures and statistical analysis.
Timed, pregnant C57BL/6 wild-type mice were sacrificed on E13.0 to E13.5, and
the embryos were harvested. Lung primordia (n  8 for each condition) were
isolated from embryos by microdissection under sterile conditions. Embryonic
lungs were placed on a 0.8-m Millipore membrane (Millipore, Billerica, MA),
supported by a metal grid (36), and cultured in defined medium. Defined me-
dium was prepared, as follows: CMRL was supplemented with 0.1% lipid-rich
albumin, insulin-transferrin-selenium, human transferrin, nonessential amino ac-
ids, Glutamax, and antibiotic-antimycotic (Invitrogen, Carlsbad, CA). Lungs
were cultured in an air-fluid interface at the level of the explants. The cultures
were maintained in 100% humidity, with an atmosphere of 95% air and 5% CO2
for 2 to 4 days. The medium was changed daily.
To monitor the effects of the “monomerizing” mutations on the HS-dependent
diffusion of FGF9 ligands, we compared the areas of dilation within whole-lung
explants after the implantation of heparin acrylic beads containing mutated and
wild-type FGF9 proteins. Beads were incubated with 200 ng/l of wild-type or
mutated FGF9 proteins overnight, washed in PBS, and implanted into the center
areas of lung explants. After 24 to 48 h of incubation, explants were photo-
graphed using a SPOT digital camera and a Leica microscope, and images were
imported into Canvas X (ACD Systems, British Columbia, Canada). The dilated
area within each explant was outlined and then measured using ImageJ software
(Image Processing and Analysis in Java). All experiments were repeated five
times. The measurements of the dilated areas induced by mutated and wild-type
FGF9 proteins were averaged, and data were processed for statistic analysis
using Student’s t test. Results were determined to be significant if P was 0.01.
Limited proteolysis of FGF9 and FGF20 proteins. To assess ligands’ sensitivity
to proteases, 2 g of FGF9 or 2.3 g of FGF20 protein (in 25 mM HEPES buffer,
pH 7.5, containing 1 M NaCl) were incubated for 2 h at ambient temperature
with increasing amounts of thermolysin, elastase (0 g, 0.0016 g, 0.016 g, 0.16
g, 1.6 g, and 16 g) or trypsin (0 g, 0.00005 g, 0.0005 g, 0.005 g, 0.05 g,
and 0.5 g). The reactions were stopped by adding SDS loading buffer and
boiling for 5 min at 95°C. The digests were electrophoresed through a 12%
SDS-polyacrylamide gel electrophoresis gel. The gel was then stained with Coo-
massie brilliant blue R-250 staining solution, and images were captured with a
Canon scanner.
Mass spectrometry analysis. To delineate trypsin cleavage sites within FGF9,
2 g of wild-type FGF9 was partially digested with 0.5 g of trypsin for 2 h at
ambient temperature. The reaction was stopped with 0.5 l of 10% formic acid
and was subjected to matrix-assisted laser desorption ionization–time of flight
(MALDI-TOF) analysis. Specifically, the sample was desalted and concentrated
with ZipTipC4 (Millipore, Billerica, MA), according to standard protocols. A
total of 1 l of eluted protein was mixed with 1 l of alpha-cyano-4-hydroxycin-
namic acid matrix (Agilent Technologies, Santa Clara, CA) and spotted onto a
384-well MALDI plate (Bruker Daltonics, Billerica, MA). All spectra were
acquired with an Autoflex MALDI-TOF mass spectrometer (Bruker Daltonics,
Billerica, MA) in linear, positive-ion mode.
Protein structure accession number. The atomic coordinates and structure
factors for FGF20 have been deposited into the RCSB Protein Data Bank
(http://www.rcsb.org/pdb/) with accession number PDB ID 3F1R.
RESULTS
FGF20 dimerizes in the crystal and in solution. Recombi-
nant full-length human FGF20 (Met-1 to Thr-211) is being
produced by CuraGen Corporation under the generic name
velafermin (CG-53135) for treatment of chemotherapy and
radiation-induced oral mucositis (30). FGF20 crystallized in
the primitive rhombohedral space group R3 with two FGF20
molecules per asymmetric unit. The crystal structure of FGF20
was solved by molecular replacement, using the FGF9 crystal
structure as a search model (PDB ID 1IHK) (50) and has been
refined to 2.5 Å. The final model consists of two FGF20 mol-
ecules (Pro-52 to Leu-208), six sulfate ions, and nine water
molecules. Data collection and refinement statistics are given
in Table 2. As anticipated, based on its high sequence identity
to FGF9 (69%), FGF20 adopts a -trefoil fold that is flanked
by N- and C-terminal helices (Fig. 1A). The helices are ori-
ented in antiparallel fashion and interact with each other
through several hydrophobic and hydrogen-bonding contacts
(Fig. 2C). Interestingly, FGF20, analogous to FGF9 (50), also
crystallized as a twofold symmetric dimer (Fig. 1B and C). The
dimer interface buries 2,198 Å2 of surface area and has a shape
complementarity value of 0.67 and a hydrophobic/polar frac-
tion of 1.4:1 (9, 33). These dimer interface parameters are
consistent with a physiological interface.
Reminiscent of the FGF9 dimer, the two FGF20 monomers
engage in homotypic interactions through their core regions, as
well as through their N- and C-terminal regions flanking the
core (Fig. 1B and 2A). W147, situated in the 8-9 turn, plays
a pivotal role at the dimer interface portion that is mediated by
the core region. W147 from one monomer engages in aromatic
and pi-cation interactions with Y70 and R193, respectively, of
the second monomer (Fig. 2B). Another prominent contact at
this interface is the hydrophobic contact between L191 (in
strand 12) of the two protomers (Fig. 2B).
The main driving forces of FGF20 dimerization, however,
are the extensive hydrophobic and hydrogen-bonding contacts
involving the N- and C-terminal regions flanking the trefoil
core (Fig. 2C). At this section of the dimer interface, L57, L60,
I63, and L64 from the N helix, together with P197, Y204,
L207, and L208 from the C terminus, form a continuous hy-
drophobic surface that binds the corresponding surface from
the other protomer in the dimer. Hydrogen bonds between
R65 and R67 from the N terminus of one protomer and D196
and E198 in the C terminus of the other protomer further
promote dimerization. In this dimer, the heparin binding sites
(HBSs) of the monomers are located on the same plane, and
each contains a bound sulfate ion (Fig. 2A).
We used size exclusion chromatography to test whether
FGF20 dimerizes in solution. When injected at 460 g/ml,
FGF20 eluted as a single peak of 65.6 kDa (Fig. 3B and C),
consistent with the theoretical size of 56.8 kDa for the FGF20
dimer. This finding suggests that FGF20 is mostly dimeric at
this concentration. Next, we injected incrementally diluted
samples of FGF20 onto the sizing column (see Materials and
Methods) and observed that the elution peak of FGF20 shifted
to its predicted monomer position, indicative of concentration-
dependent homodimerization in solution (see Table S1 in the
supplemental material). Reminiscent of FGF9 (50), FGF20
does not resolve into distinct monomer and dimer peaks on the
sizing column, suggesting that the dynamics of monomer-dimer
exchange are faster than the time scale of the size exclusion
chromatography.
To confirm further that FGF20 dimerizes, we carried out
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preliminary sedimentation velocity experiments at ligand con-
centrations of 2, 6.7, and 11.4 M in 25 mM HEPES buffer
(pH 7.5) and 1 M NaCl at 20°C. A Beckman Coulter analytical
ultracentrifuge, model XLI, was used. The sedimenting bound-
ary traces from the UV absorbance detection system were
analyzed with the SEDFIT/SEDPHAT suite of programs (56).
The sedimentation behavior of FGF20 was found to be that of
a rapid monomer-dimer equilibrium, with a Kd value between
FIG. 1. FGF20 crystal structure. (A) Cartoon diagram of an FGF20 monomer. The  strands of FGF20 are labeled according to the conventional
strand nomenclature for FGFs. The N and C helices are unique to FGF9 and FGF20 (11). NT and CT denote the N and C termini, respectively. Three
sulfate ions are shown in stick representation and colored as follows: sulfur is in yellow and oxygen is in red. The sulfate ion that is bound into the
predicted HBS of FGF20 is indicated by an asterisk. (B) Superimposition of the ribbon structures of FGF9 and FGF20 dimers. FGF9 is in green, and
FGF20 is in red. NT and CT denote the N and C termini, respectively. (C) Surface representation of the noncrystallographic FGF20 dimer. The two
FGF20 protomers are colored yellow and orange. To expose the dimer interface, the protomers are pulled apart and rotated 90 degrees about the vertical
axis, as indicated. Residues participating in the dimerization in each protomer are colored magenta and green, respectively, and are labeled on one of
the protomers. Dimerization residues that were mutated are boxed. This figure was created using PyMOL.
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30 and 100 nM (data not shown). Thus, FGF20 dimerizes more
strongly than FGF9, whose Kd is reported to be 680 nM,
according to equilibrium sedimentation (50).
Presently, there is no crystal structure of FGF20 or FGF9
bound to their cognate FGFRs. Nevertheless, when one of the
two monomers in the FGF20 dimer (Fig. 4A) or FGF9 dimer
(data not shown) is superimposed onto FGF2 in the FGF2-
FGFR1c-heparin complex (PDB ID 1FQ9) (55), it is observed
that as a dimer, FGF20 is incompatible with receptor binding.
This is due to a major overlap between the dimer interface and
FGF20’s predicted receptor binding sites in the core and N
terminus of the ligand (Fig. 3A and 4A). Thus, FGF20 must
interconvert between monomer (active) and dimer (inactive)
forms to be capable of engaging the receptor. These data led us
to propose that homodimerization autoinhibits the ability of
FGF9 and FGF20 to bind FGFR by downregulating the effec-
tive concentrations of monomeric ligands, the form capable of
binding and activating their cognate receptors (Fig. 4B).
To test this hypothesis, we decided to weaken FGF9 and
FGF20 homodimerization by introducing mutations into the
residues at their dimer interfaces. To this end, the FGF9 and
FGF20 dimer interfaces were surveyed for residues that exclu-
sively participate in each ligand’s dimerization but are not
predicted to mediate ligand binding to FGFR. Four residues in
the C-terminal region of FGF9 (D195, L200, I204, L205) and
six residues in the C-terminal region of FGF20 (D196, E198,
P197, Y204, L207, L208) were found to best satisfy these cri-
teria. All four residues in FGF9 and three of the six residues in
FGF20 (E198, L207, and L208) were substituted with alanine
either individually or in combination (Table 1). According to
our hypothesis, at any given protein concentration, the mu-
tated ligands are predicted to be less dimeric than the wild-type
ligands, and as a result, the variants are expected to bind and
activate more FGFRs than wild-type ligands (Fig. 4B). Conse-
quently, the mutated ligands should have increased biological
activity relative to that of the wild type.
Mutations in the dimer interface of FGF9 and FGF20 in-
crease the effective concentrations of monomeric ligands ca-
pable of receptor binding. We first analyzed the impact of the
mutations on ligand dimerization in solution using size exclu-
sion chromatography (Fig. 3B and C and 5A and B). Relative
to the wild-type FGF9 and FGF20 ligands, the retention times
FIG. 2. Both the core and the tail regions of FGF20 participate in dimerization. (A) A cartoon representation of the FGF20 dimer interface,
including the core and tail regions, is encircled in blue ovals. Residues mediating dimer formation are shown in stick representation and are colored
magenta and green. Two sulfate ions that are bound to the predicted HBSs of FGF20 molecules in the crystal structure are shown in stick
representation. The C traces of FGF20 residues predicted to participate in HS interactions are colored blue. (B) Detailed view of the dimer
interface involving the ligand’s core region. An aromatic and a pi-cation interaction (in surface representation) between W147 from one monomer
and Y70 and R193 of the second monomer, respectively, are indicated. (C) Detailed view of the dimer interface involving the ligand’s N- and
C-terminal regions flanking the trefoil core. The view is looking down along the twofold axis that passes through the N- and C-terminal extensions
from both of the FGF20 protomers. To generate this view, the dimer in panel A is rotated by 90 degrees around the horizontal axis. The
hydrophobic interaction between L207 of one protomer and L64 of the other is highlighted by showing the surfaces. Hydrogen bonds between R65
and R67 from the N terminus of one protomer and D196 and E198 in the C terminus of the other protomer are indicated with dashed lines. Atom
colorings are as follows: sulfur in yellow, oxygen in red, and nitrogen in blue.
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of all mutated FGF9 and FGF20 proteins increased in the
following order: wild-type FGF20  FGF20E198A 
FGF20L208A  FGF20L207A  FGF20L207A/L208A and wild-
type FGF9  FGF9D195A  FGF9I204A  FGF9L205A 
FGF9L200A  FGF9I204A/L205A  FGF9L200A/I204A/L205A 
FGF9D195A/I204A/L205A.
These data indicate that all variants are less dimeric than
their wild-type counterparts and that the mutations have an
additive effect on ligand monomerization. For example, while
wild-type FGF9 migrates at an estimated size of 48.2 kDa,
corresponding to a dimer (the predicted size is 47 kDa), the
FGF9L205A single mutant and the FGF9D195A/I204A/L205A triple
mutant migrate at estimated sizes of 33.3 kDa and 25.3 kDa,
respectively (Fig. 5A and B; Table 1). These data confirm that
the dimer interface observed in the crystal structure also me-
diates ligand dimerization in solution.
To confirm that the dimer interface mutations have shifted
the equilibrium toward monomers, the ligand form capable of
receptor binding, we employed SPR spectroscopy to compare
the binding of wild-type and mutated ligands to FGFR1c.
Wild-type and mutated ligands were immobilized either co-
valently (using amine coupling) or noncovalently (employing
Ni-nitrilotriacetic acid-oriented coupling) onto biosensor chips
at a density of 1,800 RUs, and serial dilutions of FGFR1c
were passed over the chip. Both methods of immobilization
gave similar results, and only the results using the amine cou-
FIG. 3. FGF20 dimerizes in solution. (A) Structure-based sequence alignment of human FGF9 subfamily members. Periods indicate identical
residues to the corresponding FGF9 sequence. The locations of the 12  strands defining the FGF trefoil fold and N- and C-terminal -helices
flanking the core are indicated atop of the sequence alignment. Dimerization interface residues of FGF9 and FGF20 are in orange, and residues
selected for mutagenesis are in boldface type. The predicted receptor binding residues are in cyan. Residues that mediate dimerization and are
predicted to bind receptors are colored half orange and half cyan. The predicted heparin/HS-binding residues are in yellow. The dashes represent
a gap introduced to optimize the alignment. (B) Size exclusion chromatograms of wild-type FGF20 (FGF20wt) and selected FGF20 mutants
(FGF20L207A, FGF20L207A/L208A) are shown in the indicated colors (see Table 1 for an explanation of FGF9/20 nomenclature in the text).
(C) Schematic plot showing the retention times of all FGF20 proteins, indicated with magenta arrows. Red arrows indicate the position of the sizing
standards. Blue arrows show the predicted positions of FGF20 monomer (28.4 kDa) and dimer (56.8 kDa). FGF16 elutes at fraction 71,
corresponding to a molecular size of 24 kDa. The predicted sizes of the monomeric and dimeric wild-type FGF16 (FGF16wt) are 28.6 kDa and
57.2 kDa, respectively.
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pling are shown. At all concentrations of FGFR1c tested (from
50 nM to 2 M), all mutated FGF9 and FGF20 ligands pro-
duced greater signals than the wild-type FGF9 and FGF20
molecules. For example, with 800-nM ligand injection, the re-
sponses of FGF9D195A, FGF9I204A, FGF9L205A, and FGF9L200A
single mutants were 2.9-, 4.1-, 4.2-, and 6.4-fold greater, re-
spectively, than the response of the wild type (Fig. 5C and data
not shown). FGF9I204A/L205A and FGF9L200A/I204A/L205A vari-
ants exhibited about 6.9-fold-higher plasmon resonance than
the wild type, while FGF9D195A/I204A/L205A showed an en-
hancement of 9-fold (an average from two experiments) (Fig.
5C and data not shown). Similarly, in the case of FGF20, the
single mutants FGF20E198A, FGF20L207A, and FGF20L208A, as
well as the double mutant FGF20L207A/L208A, caused increases
of 1.5-, 1.4-, 1.8-, and 2.7-fold, respectively, in plasmon reso-
nance upon receptor binding compared to that of wild-type
FGF20 (Fig. 5D and data not shown). Importantly, the in-
creases in the plasmon resonance signal conferred by the mu-
tations were proportional to the monomerizing potentials of
the mutated ligands, as indicated in Fig. 3C and 5B. Moreover,
the KD values of mutated ligands toward FGFR1c were similar
to those of the wild-type ligands. For example, the following
KD values were determined from the fitted equilibrium binding
plots: 0.89 M and 0.85 M for wild-type FGF9 and
FGF9D195A proteins, respectively (Fig. 5E). This was predict-
able because the mutated ligands were designed to conserve
FIG. 4. The FGF20 homodimer is incompatible with FGF receptor binding. (A) One of the FGF20 protomers (in red) from the FGF20 dimer
(in red and gray) is superimposed onto FGF2 in the FGF2-FGFR1c-heparin structure (PDB ID 1FQ9). Only a single FGFR1c molecule from the
FGF2-FGFR1c-heparin structure is shown. In the left and middle panels, one of the FGF20 monomers (in red) is observed to physically block
FGFR binding. For comparison, a 1:1 ratio model of the FGF20-FGFR1c complex is shown in the right panel. The C trace of FGFR1c is shown
as a green ribbon, with domain 2 and domain 3 labeled as D2 and D3, respectively. NT and CT denote the N and C termini, respectively. The view
in the middle panel is related to left panel by a 90-degree rotation along the horizontal axes. (B) Schematic model showing that dimerization
downregulates the concentrations of FGF9 and FGF20 monomers capable of receptor binding. A representation of dimeric FGF9 and FGF20
proteins incapable of receptor binding is adapted from panel A, left, while the FGF9 and FGF20 monomers competent for receptor binding are
adapted from panel A, right. The three bottom panels illustrate how single (1), double (2), and triple (3) dimer interface mutations would shift
the equilibrium toward ligand monomers. The thick arrows indicate the direction of the shift in the equilibrium. FGF9wt, wild-type FGF9; FGF20wt,
wild-type FGF20.
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the FGF-FGFR contacts, without introducing any additional
contacts with the receptor. Thus, the mutations were expected
merely to increase the available pool of monomeric ligands
that are capable of receptor binding (Fig. 4B, bottom). Taken
together, these data support our hypothesis that dimerization
serves as a mechanism to downregulate the effective concen-
trations of monomeric receptor binding-competent forms of
FGF9 and FGF20.
Mutated FGF9 and FGF20 ligands exhibit increased bioac-
tivity. The IL-3-dependent murine pro-B BaF3 cell line does
not express FGFRs and HS and therefore cannot be propa-
gated by FGFs. Forced expression of FGFRs, however, makes
FIG. 5. Dimer interface mutations increase the populations of receptor binding-competent monomers. (A) Size exclusion chromatograms of
wild-type FGF9 (FGF9wt) and selected FGF9 mutants (FGF9L205A, FGF9I204A/L205A, FGF9D195A/I204A/L205A) are shown in the indicated colors.
(B) Schematic plot showing the retention times of all FGF9 proteins, indicated with magenta arrows. Red arrows indicate the positions of the sizing
standards. Green arrows show the predicted positions of the monomer and dimer for FGF9 (monomer  23.4 kDa; dimer  46.8 kDa). (C) Repre-
sentative SPR sensorgrams of 800 nM FGFR1c injections over CM5 sensor chips containing covalently immobilized wild-type FGF9 (in black),
FGF9D195A (in red), FGF9I204A/L205A (in blue), and FGF9D195A/I204A/L205A (in green). (D) Representative SPR sensorgrams of 800 nM FGFR1c injection
over CM5 sensor chips containing covalently immobilized wild-type FGF20 (in black), FGF20L208A (in red), and FGF20L207A/L208A (in green). The
biosensor chip response is indicated on the y axis (response units) as a function of time (x axis). (E) Steady-state binding curves of two representative
FGF9 proteins (wild-type FGF9 in blue and FGF9D195A in red). The maximum response at equilibrium (Req) is plotted on the y axis as a function of
concentration (nM), and the KD values determined from the fitted curves are given. All data were analyzed utilizing BIAevaluation software.
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this cell line responsive to FGF in the presence of exogenous
heparin. Consequently, BaF3 cell-based proliferation has
served as a standard assay system for studying FGFR activation
by FGF (46). To further verify that the mutations shift the
monomer-dimer equilibrium toward monomers, the ligand
form capable of receptor binding, we compared the ability of
wild-type and mutated ligands to activate FGFR1c expressed
ectopically in BaF3 cells in either the short term by assessing
the extracellular signal-regulated kinase (ERK) activation af-
ter 10 min of stimulation or the long term by monitoring cell
proliferation over the course of 3 days. BaF3 cells transduced
with FGFR1c were starved of IL-3 and stimulated with wild-
type or mutated FGF9/20 ligands in the presence of 5 g/ml
heparin. After 10 min of stimulation, the amount of phosphor-
ylated ERK (pERK) was determined, while proliferation was
assessed every day for 3 days. Throughout the experiment, all
seven FGF9 variants exhibited a modest but reproducible in-
crease in receptor activation (ranging from enhancement of
1.3- to 2.0-fold in pERK after 10 min of stimulation [Fig. 6C]
and from enhancement of 1.2- to 1.6-fold on the third day of
proliferation assessment [Fig. 6A]) relative to that of the wild-
type ligand. Each FGF20 variant also showed modestly in-
creased activity relative to that of the wild type, reaching an
enhancement of 2.7-fold in pERK (Fig. 6D) and 1.6-fold in
cell proliferation for the FGF20L207A/L208A double mutant at
day 3 of the experiment (Fig. 6B).
Gene knockout studies in mice have shown that FGF9 is
required for the proliferation of lung mesenchyme (7). To
compare the activity of FGF9 variants in a more biologically
relevant setting, we examined BrdU incorporation by lung
mesenchymal cells in response to mutated and wild-type FGF9
proteins. Lung mesenchyme was isolated enzymatically on
E12.5 and plated on chamber slides. Cells were grown to 70 to
80% confluence, transferred to defined medium, and then
stimulated with 20 ng/ml of FGF9 proteins for 12 h, after which
BrdU incorporation was performed. As shown in Fig. 6E to I,
all FGF9 variants induced DNA synthesis, with an average of
twice as many cells as wild-type FGF9. These data suggest that
the weakening of ligand dimerization results in an increase in
the biological activities of mutated ligands in cultured cells.
Dimerization promotes the interaction of FGF9 and FGF20
with HS and restricts HS-dependent diffusion of these ligands
in ECM. The differential increases in the population of mono-
mers detected in size exclusion and SPR experiments for FGF9
and FGF20 mutants do not manifest in corresponding differ-
ential increases in the biological activities of mutated ligands in
cultured cells. For example, according to SPR data, the
FGF9D195A single and FGF9D195A/I204A/L205A triple mutants
exhibit increases of 2.9-fold and 9-fold in their monomeric
forms, respectively, relative to that of the wild-type ligand.
However, both mutants show comparable enhancements over
the wild type (1.6- and 1.4-fold, respectively) in the BaF3
receptor activation assay.
One key difference that could account for the lack of corre-
lation between the SPR assay and the receptor activation assay
is that SPR measures only a 1:1 FGF/FGFR binding event,
whereas the receptor activation assay is a readout for the net
effect of multiple binding events involved in 2:2:2 FGF/
FGFR/HS dimerization, including FGF-HS interactions.
Therefore, any negative effects of the monomerizing mutations
on the FGF-HS interactions could offset the positive contribu-
tions of mutations on FGF9 and FGF20’s biological activity.
To consider this possibility, we used SPR to compare the
impact of monomerizing mutations on the interaction of FGF9
and FGF20 ligands with immobilized heparin, a commonly
used surrogate for HS. As shown in Fig. 7A and B, relative to
the ability of wild-type ligands, all of the mutants had a re-
duced ability to interact with immobilized heparin. Impor-
tantly, the least-dimeric variants exhibited the greatest loss in
HS binding (compare Fig. 7A with 5B and Fig. 7B with 3C),
indicating that dimerization enhances the binding of FGF9 and
FGF20 to HS. Since SPR signaling is directly proportional to
the mass of bound analyte, the reduction in the plasmon signal
observed for the mutants may not be necessarily due to the
actual loss in the affinity for heparin but rather could simply
reflect the fact that the wild type binds predominantly as a
dimer, while the mutated variant binds as a monomer. To
confirm that the monomerizing mutations truly impact the
affinity of the FGF-HS interactions, we compared the ionic
strength required to elute wild-type FGF9 and the
FGF9D195A/I204A/L205A mutant from a heparin affinity col-
umn. This analysis showed that FGF9D195A/I204A/L205A elutes
at 780 mM NaCl, which is about 220 mM less salt than that
required to elute wild-type FGF9 (data not shown), suggesting
that homodimerization augments the affinity of the FGF9 sub-
family members for HS.
Emerging data show that FGF-HS interactions can regulate
the biology of FGFs by controlling the diffusion rate and thus
FGF gradients in the HS-abundant ECM. This is illustrated by
the FGF19 subfamily, whose members interact poorly with HS
and consequently are not trapped in the ECM of the secreting
cells, thus enabling them to act in an endocrine fashion (15,
28). Moreover, we have recently demonstrated that a differ-
ence in the shapes of HS-dependent gradients underlies the
divergent roles of FGF7 and FGF10 in branching morphogen-
esis (H. P. Makarenkova and M. Mohammadi, unpublished
data). Since our data show that dimerization enhances FGF9’s
interactions with HS, we decided to address the role of dimer-
ization in regulating ligand diffusion in ECM. It has been
recently reported that implantation of heparin acrylic beads
loaded with FGF9 into ex vivo lung organ explants causes
significant dilation of the lung epithelial structures around the
bead (8). We adopted this assay to compare the diffusion rates
of wild-type and mutated FGF9 ligands. We reasoned that due
to their decreased HS-binding affinity, the mutated FGF9 li-
gands will diffuse and induce lung dilation further away from
the FGF source. Wild-type or mutated FGF9 ligands were
bound onto heparin acrylic beads, which were then implanted
into whole-lung explants. Compared to wild-type FGF9, all
mutated ligands induced dilation of a wider area around the
bead (Fig. 7C to K). The dilated areas around the FGF9D195A,
FGF9L200A/I204A/L205A, and FGF9D195A/I204A/L205A beads were
approximately 30 to 35% larger than that around the bead
containing wild-type protein (compare Fig. 7D with F and Fig.
7G with I or J; see also Fig. 7K). Together, these experiments
suggest that dimerization confines the radius of FGF9 biologic
action by promoting ligand’s HS binding and thus restricting its
HS-dependent diffusion.
Heparin shifts the equilibrium toward the dimer. As HSs
constitute an integral part of FGF signaling in vivo (reviewed
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FIG. 6. FGF9 and FGF20 mutants exhibit enhanced proliferative activities. (A) Growth curve of BaF3 cells overexpressing FGFR1c stimulated
with 100 ng/ml of wild-type or mutated FGF9 and 5 g/ml heparin in the absence of IL-3. (B) Growth curve for BaF3/FGFR1c cells stimulated
with 100 ng/ml of wild-type or mutated FGF20 and 5 g/ml heparin in the absence of IL-3. Experiments were performed in triplicate and repeated
twice, with similar results. (C, D) Analysis of phospho-p44/42 mitogen-activated protein kinase (pERK) upon stimulation with 100 ng/ml of
exogenous wild-type and mutated FGF9 (C) or wild-type and mutated FGF20 proteins (D) supplemented with 5 g/ml of heparin. pERK activation
is represented as a measure of mean fluorescence intensity. (E to H) Fluorescence images showing BrdU incorporation in lung mesenchymal cells
treated with wild-type FGF9 (E), FGF9L200A (F), FGF9D195A (G), and FGF9L200A/I204A/L205A (H). BrdU staining is in green, and DAPI staining
is in blue. (I) Quantification of BrdU incorporation in wild-type FGF9 and FGF9 variants. Percent BrdU labeled in lung mesenchymal cells after
lack of treatment (None) or after 12 h of treatment with wild-type FGF9 and FGF9 mutants. The “n” indicates the number of experiments used
for averaging.
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FIG. 7. The FGF9 and FGF20 mutants bind heparin more weakly and induce wider dilation of lung epithelium in ex vivo lung explants than
the wild type. (A) SPR analysis of wild-type and mutated FGF9 interactions with heparin. Presented are the sensorgrams of the representative 80
nM injections of FGF9 proteins onto a heparin-immobilized chip. (B) Sensorgrams of 60 nM injections of wild-type and mutated FGF20 proteins
passed over a heparin-coated chip. The biosensor chip response is indicated on the y axis (response units) as a function of time (x axis). (C to J)
Mouse embryonic lungs were explanted on E13.0 and E13.5, and heparin acrylic beads containing bovine serum albumin (BSA) (C), wild-type
FGF9 (D, G), or the indicated FGF9 mutants (E, F, H, I, and J) were inserted into the central area of the explant. Outlined in red are dilated
areas around the beads, measured after explants were cultured for an additional 24 to 48 h. (K) A statistical quantification of the dilated area
around the bead after application of wild-type FGF9 or FGF9 dimerization mutants.
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in references 18 and 37), they are a likely component to influ-
ence the dimerization state of the ligand in a cell. The way HSs
are thought to accomplish this is by serving as a matrix for
concentrating the ligand on the cell surface and ECM.
We reasoned that if dimerization increases heparin binding,
then the presence of heparin should increase dimerization. To
test whether HS can shift the monomer-dimer equilibrium
toward the dimer, we added increasing concentrations of hep-
arin DS to wild-type FGF9 and analyzed the mixtures by size
exclusion chromatography. Consistent with our prediction,
DS shifts the wild-type FGF9 toward the oligomeric state
(Fig. 8A). We next tested the ability of DS to dimerize
FGF9D195A/I204A/L205A and found that DS is less effective in
dimerizing the mutated ligand (Fig. 8B). Specifically, while a
1:1 ratio of wild-type FGF9 to DS was sufficient to entirely shift
the FGF9 toward the highest multimer (8 molecules of
FGF9) (Fig. 8A), the same amount of DS shifts the
FGF9D195A/I204A/L205A peak only to approximately a 50:50
mixture of monomer/dimer (Fig. 8B). These data are consis-
tent with our size exclusion (Fig. 3B and C) and SPR data (Fig.
7A and B), showing that the mutated ligands are more mono-
meric and have reduced affinity for HS. Therefore, we can
conclude that the observed differences in bioactivity of the
wild-type and mutated ligands are due to the differences in
their ability to homodimerize.
To study the effect of HS on the FGFR activation in BaF3
system, we compared the extents of activation for wild-type
FGF9 and FGF9D195A/I204A/L205A by varying the amount of
added heparin while keeping the ligand concentration con-
stant. We report that the amount of heparin required to produce
maximal bioluminescence responses for both proteins is in the
range of 0.625 to 5 g/ml, while at over 30 g/ml of added
heparin, this difference becomes negligible (Fig. 8C). These find-
ings are consistent with our hypothesis that at a low concentration
of heparin, there is a large proportion of the monomeric fraction
of FGF9D195A/I204A/L205A compared to that of wild-type FGF9.
When the concentration of heparin is raised so that both wild-
type FGF9 and FGF9D195A/I204A/L205A exist mostly as dimers,
the difference in activation is no longer existent.
Lastly, we chose to perform the cell-based assay using a 300
FIG. 8. Heparin shifts the monomer-dimer equilibrium toward the dimer. (A, B) Size exclusion chromatograms of 17 M of wild-type
FGF9 (A) or FGF9D195A/I204A/L205A (B), with various amounts (0, 2.1, 4.3, 8.5, 17, 34, 68, and 136 M) of heparin DS. M, D, T, and O
represent monomer, dimer, tetramer, and octamer peaks, respectively. (C) Growth curve of BaF3 cells overexpressing FGFR1c stimulated
with 100 ng/ml of wild-type FGF9 (in blue) or FGF9D195A/I204A/L205A (in red) and various heparin concentrations (0, 0.3125, 0.625, 1.25, 2.5,
5, 10, 20, 40, and 80 g/ml) in the absence of IL-3. (D) Quantification of BrdU incorporation in variants stimulated with 300 nM wild-type
FGF9, FGF9D195A, or FGF9D195A/I204A/L205A. Percent BrdU labeled in lung mesenchymal cells after lack of treatment (None) or after 12 h
of treatment with wild-type FGF9 and FGF9 mutants. The “n” indicates the number of experiments used for averaging.
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nM ligand concentration, which is close to the Kd for FGF9
dimerization (680 nM). At this concentration, 25% of the
wild-type ligand should exist as dimer, whereas the mutants
should still be mostly monomeric. Our data show that compared
to wild-type FGF9, FGF9D195A and FGF9D195A/I204A/L205A still
produced an enhancement of 4.5- and 7.5-fold in the ratio of
proliferating cells, respectively (Fig. 8D).
The positive effect conferred by the monomerizing muta-
tions on receptor binding alongside their negative effects on
HS binding would then explain why the increases in the pop-
ulation of the monomers observed in solution (size exclusion
and SPR experiments) do not manifest in corresponding in-
creases in the biological activities of mutated ligands in cul-
tured cells.
DISCUSSION
Structural and biochemical studies show that the compo-
nents of growth factor signaling pathways are subject to auto-
inhibition to combat uncontrolled activation. Indeed, loss of
these autoinhibitory mechanisms is often the culprit of human
pathologies. For example, in FGFR kinases, pathogenic muta-
tions lead to constitutive kinase action by disengaging the au-
toinhibitory molecular brake at the kinase hinge region (5).
Numerous naturally occurring mutations in the JM regions of
KIT, PDGFR, and FLT3 relieve the autoinhibition provided
by JM region interaction with the ATP binding cleft and active
site, resulting in constitutive kinase activity that gives rise to
cancer (reviewed in reference 21). Recent studies also begin to
show the existence of autoinhibition in extracellular regions of
receptor tyrosine kinases (RTKs). In the absence of epidermal
growth factor, the extracellular domain of the epidermal
growth factor receptor is maintained in an autoinhibited con-
formation by specific intramolecular contacts between the
“dimerization arm” in domain II and a homologous region in
domain IV to prevent high-affinity binding of the ligand (6, 12).
In FGFR, the D1 and D1-D2 linker region, although not nec-
essary for ligand binding, can indirectly modify the ligand and
heparin binding affinities of the D2-D3 region through in-
tramolecular interactions (reviewed in reference 38). D1 is
proposed to operate in concert with the acid box region in the
D1-D2 linker to occlude the ligand binding site and HBS of
FGFRs, thereby preventing accidental receptor activation in
the basal state (44).
In this study, we provide evidence of autoinhibition in FGF
signaling at the level of the ligand by demonstrating that ho-
modimerization autoinhibits signaling activity of FGF9 and
FGF20 ligands. We show that dimerization represses receptor
binding and limits HS-dependent diffusion of FGF9 and
FGF20. We also report here that FGF20 dimerizes as much as
10-fold more strongly than FGF9, according to analytical
ultracentrifugation (AUC), although different AUC method-
ologies were used under slightly different conditions. Interest-
ingly, we found that FGF16, the third member of the subfam-
ily, migrates as a monomer on the gel filtration column (Fig.
3B). Preliminary SPR studies of FGF16 binding affinity to
heparin show that FGF16 binds to heparin the weakest com-
pared to FGF9 and FGF20 (see Fig. S1 in the supplemental
material). The primary sequences of the predicted HBS of the
FGF9 subfamily members are highly conserved (Fig. 3A), and
therefore, the differences in HS binding among subfamily
members cannot be explained by sequence variation at the
HBS. Importantly, these data further corroborate our model
that dimerization positively regulates the FGF9 subfamily’s
binding affinity for HS. Sequence alignment of the FGF9 sub-
family shows that FGF16 diverges from FGF9 and FGF20 at
its C terminus, the key region mediating ligand dimerization
(Fig. 3A). Based on these findings, we propose that the mem-
bers of the FGF9 subfamily have different propensities to ho-
modimerize, suggesting that gradations of autoinhibitory con-
trol by dimerization exist for FGF9/16/20 ligands.
The monomerizing mutations map onto the dimer region
that is opposite of the ligands’ predicted HS-binding sites (Fig.
2A), suggesting that the mutations impact HS binding of the
ligands indirectly. One likely mechanism would be if ligand
monomerization increases the intrinsic thermal motion of the
mutant ligands. The increased flexibility of the HBSs of the
mutated FGF9 and FGF20 ligands could then impose an en-
tropic loss upon HS binding and could account for the reduc-
tions in HS binding of the mutated ligands. Sensitivity to pro-
teases can be used to study protein flexibility. We tested the
impact of the mutations on the ligands’ intrinsic flexibility by
comparing the sensitivity of wild-type and mutated ligands to
specific (trypsin) and nonspecific (thermolysin and elastase)
proteases. This assay showed that the more monomeric the
mutants are, the more susceptible to proteolysis they become
(see Fig. S2 and S4A in the supplemental material). Specifi-
cally, cleavage profiles of partially digested wild-type FGF9
and FGF9D195A/I204A/L205A (2 g each) with 0.5 g trypsin
show that while wild-type FGF9 gives a spread of at least seven
identifiable digestion bands, FGF9D195A/I204A/L205A is almost
entirely digested (see Fig. S4A, compare lanes 3 and 9, in the
supplemental material). In order to identify the cleavage sites/
products of limited trypsin digestion of wild-type FGF9 at this
concentration, we employed MALDI-TOF analysis. We iden-
tified three of the digested fragments (G48-S208, G59-S208,
and T70-R190). The cleavage sites for two later products ap-
pear to map within the dimer interface (see Fig. S4B to E in
the supplemental material). Taken together, these data dem-
onstrate that while an increase in the thermal flexibility of
monomers could account for their reduced HS binding relative
to that of wild-type ligands, it cannot be ruled out, however,
that the appearance of expedited digestion of the mutated
derivative is due to the better access of the protease to its
substrate within the dimer interface. We predict that a combi-
nation of two events is a likely possibility; however, further
studies are necessary.
Our data set the stage for the engineering of analogues of
FGF9/20 with several potential therapeutic applications. Re-
combinant human FGF20, velafermin, is currently in phase 1/2
clinical development for the treatment of chemotherapy/radi-
ation-induced oral mucositis due to FGF20 cyto- and radio-
protective properties (1, 2, 34). Thus, FGF20 analogues may
well be the next generation of velafermin, with increased bio-
activities for use in radiation-induced mucositis.
FGF20 analogues may play beneficial role for the treatment
of Parkinson’s disease. Single-nucleotide polymorphisms in the
FGF20 gene have been associated with Parkinson’s disease
(64). Consistent with this finding, in situ hybridization experi-
ments have shown that FGF20, as well as its cognate receptor
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(FGFR1c), is expressed in the substantia nigra pars compacta,
a region of the brain where dopaminergic (DA) neurons de-
generate in Parkinson’s disease (42, 43). Studies with cultured
DA neurons show that FGF20 is capable of promoting the
survival of rat DA neurons in serum-free medium or in the
presence of cytotoxic concentrations of glutamate (43). FGF20
has also been shown to be able to differentiate pluripotent
stem cells into DA neurons (61) and improve DA neuron
survival after transplantation (54). Hence, FGF20 analogues
could be used for differentiation, propagation, and mainte-
nance of DA neurons for cell replacement therapy for Parkin-
son’s disease.
Additionally, FGF20 analogues can prove to be valuable
tools in cardiovascular biology. Myocardial FGF9 subfamily
signaling regulates coronary vascular development by trigger-
ing a wave of hedgehog activation that is essential for vascular
endothelial growth factor A (VEGF-A), VEGF-B, VEGF-C,
and angiopoietin-2 expression (31). FGF9/16/20 agonists can
serve as agents to increase coronary vessel density and perfu-
sion. Lastly, engineered FGF9 ligands may also be used to
stimulate the growth of lung stem/progenitor cells. Taken to-
gether, our data provide a framework for the discovery of novel
FGF9 and FGF20 agents with desired biological activity for
use in both basic and translational research.
While the manuscript was in revision, a study by Harada et
al. was reported (17). This work further strengthens our hy-
pothesis that homodimerization controls the FGF9 subfamily’s
receptor binding and HS-dependent diffusion in the ECM.
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